Clinical Trial

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT07171606
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions First-line Advanced NSCLC Patients
Enrollment 240 participants
Start Date 2025-10-24
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-18